Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

17.64 -0.62 (-3.40%)
Streaming Delayed Price Updated: 2:53 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Apellis Pharmaceuticals, Inc. Class Action
From Robbins LLP
Via Business Wire
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
The company is already under scrutiny after reports of side effects tied to Syfovre. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $750,000 to Contact the Firm
Via ACCESSWIRE
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
From Bernstein Liebhard LLP
Via GlobeNewswire
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)
From Robbins LLP
Via Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023
Via Benzinga
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat
Apellis crashed after Syfovre safety issues continued to plague the stock. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Via Benzinga
Apellis Pharmaceuticals Stock Slips Despite Q2 Sales Beat Thanks To Syfovre, Empaveli
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the  
Via Benzinga
Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.